>
Switch to:

Orgenesis Altman Z-Score

: -2.86 (As of Today)
View and export this data going back to 2010. Start your Free Trial

Warning Sign:

Altman Z-score of -2.88 is in distress zone. This implies bankrupcy possibility in the next two years.

Orgenesis has a Altman Z-Score of -2.86, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for Orgenesis's Altman Z-Score or its related term are showing as below:

NAS:ORGS' s Altman Z-Score Range Over the Past 10 Years
Min: -436.86   Med: -1.4   Max: 110.18
Current: -2.88

-436.86
110.18

During the past 13 years, Orgenesis's highest Altman Z-Score was 110.18. The lowest was -436.86. And the median was -1.40.


Orgenesis Altman Z-Score Historical Data

The historical data trend for Orgenesis's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orgenesis Annual Data
Trend Nov11 Nov12 Nov13 Nov14 Nov15 Nov16 Nov17 Nov18 Dec19 Dec20
Altman Z-Score
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.40 -1.58 -0.21 -1.18 -2.41

Orgenesis Quarterly Data
Nov16 Feb17 May17 Aug17 Nov17 Feb18 May18 Aug18 Nov18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
Altman Z-Score Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.70 -2.41 -1.30 -0.61 -1.25

Competitive Comparison

For the Biotechnology subindustry, Orgenesis's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Orgenesis Altman Z-Score Distribution

For the Biotechnology industry and Healthcare sector, Orgenesis's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where Orgenesis's Altman Z-Score falls into.



Orgenesis Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Orgenesis's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*0.3493+1.4*-1.5544+3.3*-0.9955+0.6*2.8431+1.0*0.474
=-2.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Sep. 2021:
Total Assets was $65.20 Mil.
Total Current Assets was $36.34 Mil.
Total Current Liabilities was $13.57 Mil.
Retained Earnings was $-101.36 Mil.
Pre-Tax Income was -10.084 + -2.725 + -0.167 + -52.981 = $-65.96 Mil.
Interest Expense was -0.254 + -0.271 + -0.253 + -0.266 = $-1.04 Mil.
Revenue was 8.676 + 10.545 + 9.389 + 2.296 = $30.91 Mil.
Market Cap (Today) was $62.39 Mil.
Total Liabilities was $21.94 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(36.341 - 13.566)/65.204
=0.3493

X2=Retained Earnings/Total Assets
=-101.356/65.204
=-1.5544

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-65.957 - -1.044)/65.204
=-0.9955

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=62.387/21.943
=2.8431

X5=Revenue/Total Assets
=30.906/65.204
=0.474

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

Orgenesis has a Altman Z-Score of -2.86 indicating it is in Distress Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


Orgenesis  (NAS:ORGS) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


Orgenesis Altman Z-Score Related Terms

Thank you for viewing the detailed overview of Orgenesis's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Orgenesis Business Description

Orgenesis logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Traded in Other Exchanges
Address
20271 Goldenrod Lane, Germantown, MD, USA, 20876
Orgenesis Inc is a part of the healthcare sector. It is a fully-integrated biopharmaceutical company focused on developing trans-differentiation technologies for diabetes and vertically integrating manufacturing that can optimize its abilities to scale-up its technologies for clinical trials and eventual commercialization. The group operates in two segments namely CDMO and POC. The company is also engaged in applying its disciplined execution to emerging technologies of other cell therapy markets in such areas as cell-based cancer immunotherapies and neurodegenerative diseases.
Executives
Sidransky David director JOHNS HOPKINS UNIVERSITY 720 RUTLAND AVENUE BALTIMORE MD 21205
Reithinger Neil officer: CFO, Treasurer and Secretary 14950 N. 83RD PLACE SUITE 1 SCOTTSDALE AZ 85260
Philips Mario director C/O ATMI, INC DANBURY CT 06810
Ferber Sarah officer: Chief Scientific Officer 17B HAHASKALA STREET TEL AVIV L3 67890
Yachin Guy director 7 ORCHARD WAY N POTOMAC MD 20854
Nanda Ashish director 2301, 23RD FLOOR, TIFFANY TOWERS CLUSTER W, JLT, DUBAI, UAE DUBAI C0 4452
Bedoret Denis officer: See Remarks 48, RUE AUGUSTE PICCARD GOSSELIES C9 6041
Universite Libre De Bruxelles other: less than 10% AVENUE F, ROOSEVELT, 50 BRUSSELS C9 1050
Theodorus Ii Sa other: less than 10% ALLEE DE LA RECHERCHE, 12 BRUSSELS C9 1070
Theodorus Sca other: less than 10% ALLEE DE LA RECHERCHE, 12 BRUSSELS C9 1070
Belenger Olivier other: less than 10% DIEWEG, 69 BRUSSELS C9 1070
Shvartz Oded 10 percent owner 130 BIRUINTEI BVD. PANTELIMON, ILFOV S5 0000000
Bultot Hugues director AVENUE DE L??HORIZON 24 WOLUWE SAINT PIERRE C9 1150
Buyse Chris Georges Frans director BAILLET LATOURLEI 119A BRUSSELS C9 2390
Tenne Joseph officer: CFO Treasurer Secretary 6225 NEIL ROAD, SUITE 300 C/O ORMAT TECHNOLOGIES, INC. RENO NV 89511

Orgenesis Headlines

From GuruFocus

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)